<< Vanda Pharmaceuticals announces financial results for the third quarter of 2009 | Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | עִבְרִית | Русский | Svenska | Polski

Kinetic Concepts receives approval from MHLW in Japan to sell its V.A.C. Therapy System

Published on November 2, 2009 at 7:41 AM · No Comments

Kinetic Concepts, Inc. (NYSE: KCI) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted final regulatory approval for KCI to market and sell its innovative V.A.C.® Therapy System in the country.

“Japan has a deep heritage of providing outstanding medical care, and the people of KCI are pleased and humbled to have the opportunity to serve this market,” said Catherine Burzik, KCI president and CEO. “What makes us especially proud is that our clinically proven V.A.C.® Therapy System will fill a real unmet medical need in Japan for hard-to-heal wounds.”

Reimbursement applications have been submitted following regulatory approval. Operational preparations, including employee hiring, are underway for commercial launch at the time of reimbursement approval. KCI anticipates reimbursement approval in the first half of 2010.

Source: Kinetic Concepts, Inc.

Posted in: Pharmaceutical News

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading